Hewlett Packard to pay $61 mil. for 14% stake in i-Stat.
This article was originally published in The Gray Sheet
Executive SummaryHEWLETT PACKARD'S $61 MIL. INVESTMENT IN i-STAT gives HP access to i-Stat's "thin-film" biosensor blood chemistry technology for integration into its OmniCare patient-monitoring system. The two companies announced on June 23 the signing of a strategic alliance -- under negotiation for nearly a year -- calling for HP to purchase 2.1 mil. preferred shares of i-Stat for $28.50 each. The deal will give HP a 14% fully-diluted stake in Princeton, New Jersey-based i-Stat.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.